Sunday, December 15, 2024

Pfizer's Partner in mRNA Gene Therapy 'Vaccines' is Testing One for Lung Cancer

by Scott Creighton

Good morning.

German based BioNTech is in the process of testing a new lung cancer 'vaccine' called BNT116 which is based on the mRNA model they helped bring about with the Covid-19 'vaccines' they made in partnership with Pfizer.

It's for non-small cell lung cancer (NSCLC)

'Drawing on technologies used in the creation of COVID-19 immunizations, BioNTech launched its first clinical trials involving the new vaccine in August 2024. While media outlets praised the trials for their promise and potential, most of the coverage has focused on the company’s skyrocketing valuations, leaving many to wonder how the vaccine actually works on a scientific level, why it arrived at the time that it did, and when (if ever) it will become a widely available form of treatment...

“The role of mRNA is to carry protein information from the DNA in a cell’s nucleus to the cell’s cytoplasm (watery interior),” notes the National Human Genome Research Institute, “where the protein-making machinery reads the mRNA sequence and translates each three-base codon [sequences made up of the DNA molecules adenine (A), cytosine (C), guanine (G), and thymine (T)] into its corresponding amino acid in a growing protein chain.” Big Think

This is reported as being very exciting news for the Western world hailing the glorious mRNA tech as some kind of VunderDrug (sieg heil) which only killed million or so test subjects to work out the kinks.

However... Cuba has had a working, safe, well tested NSCLC vaccine on the market... since 2011. And oh yeah... it costs about a dollar to produce... and the ebil soOOoooOoocialist country... gives it to their people (and you to if you can get there)... for free.

Damn commies. How dare they ignore profits?!?


'The vaccine was developed by the Center of Molecular Immunology, Havana, Cuba, and made available to the Cuban population in 2011.[3][4] There are agreements in place to test it in the United States, Japan, and some European countries.[5] It is currently available in Cuba, Belarus, Colombia, Bosnia and Herzegovina, Peru and Paraguay.[6] In October 2015 Serbia's Institute of Virology, Vaccines and Sera (AKA Torlak Institute) signed a memorandum for use in 30 patients as part of a study.[7] CimaVax is relatively cheap to produce and store, and has low toxicity.[5] It costs approximately USD $1 per shot to manufacture.[8]: 144  Side effects of the vaccine appear to be mild, and include chills, fever, and feeling sick...

The United States embargo against Cuba forbids US citizens from seeking medical treatment in Cuba.' Wiki

Get that? You folks in the U.S. and the rest of the Westernized world can't get this inexpensive treatment for cancer in spite of the fact that it's been around for 13 years and is, according to PubMed... effective at saving lives.

Cus you know... profit margins are more important than your lives. Of course, the wealthy stockholders who help convince our congress that we have to maintain the restrictions on Cuba, they can (and do) fly their private jets down to Cuba whenever they have anything more than a common cold so... there is that.

'Results: 106 patients diagnosed with advanced NSCLC at the National Institute of Oncology and Radiobiology, who had at least stable disease after first-line therapy, were enrolled in the study. The initial four CIMAvax-EGF doses were administered every 2 weeks and then, patients received monthly re-immunizations. Globally, 52.8% of the patients were 65 years or older, 77.4% had an ECOG 1 and 62.3% had an adenocarcinoma. The median survival time (MST) was 14.6 months. Patients younger than 65 years had a MST of 16.7 months and subjects with ECOG 0 survived for 29 months. The median progression-free survival was 8.16 months. Overall, 36.8% and 19.8% of patients maintained disease control at 6 and 12 months, respectively. The most frequent adverse events were pain (27.3%) or induration (7.3%) at the injection site and local erythema (10.9%).

Conclusion: CIMAvax-EGF, as an EGF depleting immunotherapy used as switch-maintenance was safe and effective in patients with NSCLC.' PubMed

As you would expect in our corrupt medical treatment industry, you can find a variety of studies showing all sorts of results when it comes to the usefulness and efficacy of the Cuban vaccine.

However, it's clearly doing well enough to still be in use in Cuba and a number of other nations and an American company has been granted the rights to begin collaborating and testing the product here in the states.

Makes you wonder how many lives could have been prolonged or saved altogether had we not been punishing the Cuban people for preferring a form of government our glorious Captains of Industry don't like?

It's a good thing we got our priorities straight. Profits over people baby. It's the 'Merikan Way!

2 comments:

  1. https://alethonews.com/2024/12/15/fda-advisers-bullish-on-rsv-shots-for-kids-even-as-safety-signals-shut-down-moderna-trials/
    FDA Advisers Bullish on RSV Shots for Kids, Even as Safety Signals Shut Down Moderna Trials

    ReplyDelete
  2. And over in EU, on the fake food front, see what they're approving.
    Soon with fake running blood from GMO yeast!

    https://gmwatch.org/en/106-news/latest-news/20489
    The European Food Safety Authority’s (EFSA)’s favorable opinions on a GMO yeast-derived “fake meat” ingredient are full of data gaps and errors and put public health at risk, according to a new analysis by Claire Robinson of GMWatch and Prof Michael Antoniou.

    EFSA’s food additives (FAF) and GMO Panels said they had no safety concerns about Impossible Foods’ application for EU market approval of its soy leghemoglobin product (LegH Prep), which is derived from a genetically modified version of the yeast K. phaffii. LegH Prep is intended to give the company’s meat substitute products, such as the Impossible Burger, a “bleeding” appearance and a meaty flavor.

    ReplyDelete